RE:yankee- you make a good pointI believe the simple explanation is... much of this larger market is still treatable with BCG. BCG sells at a fraction of the price of what is proposed for MCNA. MCNA is targeted at BCG-refractory patients (tough challenge). There is virtually no competition for this subset (excluding Valstar, by Endo, with its marginal efficacy and only for treatment of CIS tumours). So a much smaller market for MCNA but potentially extremely profitable. Off-label will happen and that will be a bonus. Hopefully others will correct me quickly if I am wrong. rg